GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acura Pharmaceuticals Inc (OTCPK:ACUR) » Definitions » Piotroski F-Score

Acura Pharmaceuticals (Acura Pharmaceuticals) Piotroski F-Score : 0 (As of Apr. 25, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Acura Pharmaceuticals Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Acura Pharmaceuticals has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Acura Pharmaceuticals's Piotroski F-Score or its related term are showing as below:


Acura Pharmaceuticals Piotroski F-Score Historical Data

The historical data trend for Acura Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acura Pharmaceuticals Piotroski F-Score Chart

Acura Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 1.00 3.00 4.00 -

Acura Pharmaceuticals Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 1.00 2.00 2.00 -

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec21) TTM:Last Year (Dec20) TTM:
Net Income was -0.259 + -0.387 + -0.262 + 0.029 = $-0.88 Mil.
Cash Flow from Operations was -0.313 + -0.194 + 0.191 + -0.426 = $-0.74 Mil.
Revenue was 0.644 + 0.613 + 0.27 + 0.036 = $1.56 Mil.
Gross Profit was 0.644 + 0.613 + 0.27 + 0.036 = $1.56 Mil.
Average Total Assets from the begining of this year (Dec20)
to the end of this year (Dec21) was
(1.736 + 1.918 + 1.896 + 1.406 + 0.86) / 5 = $1.5632 Mil.
Total Assets at the begining of this year (Dec20) was $1.74 Mil.
Long-Term Debt & Capital Lease Obligation was $0.17 Mil.
Total Current Assets was $0.37 Mil.
Total Current Liabilities was $0.52 Mil.
Net Income was -0.595 + 0.308 + -0.678 + -0.243 = $-1.21 Mil.

Revenue was 1.091 + 1.351 + 0.41 + 0.718 = $3.57 Mil.
Gross Profit was 1.091 + 1.351 + 0.41 + 0.718 = $3.57 Mil.
Average Total Assets from the begining of last year (Dec19)
to the end of last year (Dec20) was
(2.562 + 2.004 + 2.536 + 2.199 + 1.736) / 5 = $2.2074 Mil.
Total Assets at the begining of last year (Dec19) was $2.56 Mil.
Long-Term Debt & Capital Lease Obligation was $0.11 Mil.
Total Current Assets was $1.18 Mil.
Total Current Liabilities was $7.52 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Acura Pharmaceuticals's current Net Income (TTM) was -0.88. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Acura Pharmaceuticals's current Cash Flow from Operations (TTM) was -0.74. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec20)
=-0.879/1.736
=-0.50633641

ROA (Last Year)=Net Income/Total Assets (Dec19)
=-1.208/2.562
=-0.47150664

Acura Pharmaceuticals's return on assets of this year was -0.50633641. Acura Pharmaceuticals's return on assets of last year was -0.47150664. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Acura Pharmaceuticals's current Net Income (TTM) was -0.88. Acura Pharmaceuticals's current Cash Flow from Operations (TTM) was -0.74. ==> -0.74 > -0.88 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec21)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec20 to Dec21
=0.167/1.5632
=0.10683214

Gearing (Last Year: Dec20)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec19 to Dec20
=0.105/2.2074
=0.04756727

Acura Pharmaceuticals's gearing of this year was 0.10683214. Acura Pharmaceuticals's gearing of last year was 0.04756727. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec21)=Total Current Assets/Total Current Liabilities
=0.372/0.515
=0.7223301

Current Ratio (Last Year: Dec20)=Total Current Assets/Total Current Liabilities
=1.179/7.522
=0.15674023

Acura Pharmaceuticals's current ratio of this year was 0.7223301. Acura Pharmaceuticals's current ratio of last year was 0.15674023. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Acura Pharmaceuticals's number of shares in issue this year was 75.812. Acura Pharmaceuticals's number of shares in issue last year was 32.368. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1.563/1.563
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=3.57/3.57
=1

Acura Pharmaceuticals's gross margin of this year was 1. Acura Pharmaceuticals's gross margin of last year was 1. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec20)
=1.563/1.736
=0.90034562

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec19)
=3.57/2.562
=1.39344262

Acura Pharmaceuticals's asset turnover of this year was 0.90034562. Acura Pharmaceuticals's asset turnover of last year was 1.39344262. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+1+0+0+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Acura Pharmaceuticals has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Acura Pharmaceuticals  (OTCPK:ACUR) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Acura Pharmaceuticals Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Acura Pharmaceuticals's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Acura Pharmaceuticals (Acura Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
616 N. North Court, Suite 120, Palatine, IL, USA, 60067
Acura Pharmaceuticals Inc is a specialty pharmaceutical company based in the United States. It is engaged in the research, development, and commercialization of technologies and products intended to address medication abuse and misuse. The company's product portfolio includes Limitx, Oxaydo, and Nexafed.
Executives
Bruce F Wesson director 1827 PACIFIC ST BROOKLYN NY 11233
William G Skelly director C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT, SUITE 120 PALATINE IL 60067
George K Ross director 1350 TREAT BLVD SUITE 250 WALNUT CREEK CA 94596
James F Emigh officer: VP, Corporate Development
Immanuel Thangaraj director 10001 WOODLOCH FOREST DRIVE SUITE 175 THE WOODLANDS TX 77380
Robert A Seiser officer: VP, Treasurer & Controller C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT SUITE 120 PALATINE IL 60067
Robert B Jones officer: President & CEO C/O ACURA PHARMACEUTICALS, INC. 616 N NORTH COURT PALATINE IL 60067
Albert W Brzeczko officer: VP Pharmaceutical Sciences APT C/O ACURA PHARMACEUTICALS, INC. 660 N. NORTH COURT PALATINE IL 60067
Peter A Clemens officer: Senior VP & CFO C/O HALSEY DRUG CO INC 1827 PACIFIC STREET BROOKLYN NY 11233
Abuse Deterrent Pharma, Llc 10 percent owner 333 EAST MAIN STREET SUITE 200 LOUISVILLE KY 40202
Claudius Llc 10 percent owner C/O GALEN ASSOCIATES 610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020
John Schutte 10 percent owner 9707 SHELBYVILLE ROAD, LOUISVILLE KY 40233
Galen Partners Iii L P 10 percent owner 610 FIFTH AVE 5TH FL NEW YORK NY 10020
Galen Management, Llc 10 percent owner 680 WASHINGTON BLVD, STAMFORD CT 06901
Galen Employee Fund Iii Lp 10 percent owner 610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020

Acura Pharmaceuticals (Acura Pharmaceuticals) Headlines